JP2019034924A - 妊娠中の母子の健康状態改善剤 - Google Patents
妊娠中の母子の健康状態改善剤 Download PDFInfo
- Publication number
- JP2019034924A JP2019034924A JP2018013395A JP2018013395A JP2019034924A JP 2019034924 A JP2019034924 A JP 2019034924A JP 2018013395 A JP2018013395 A JP 2018013395A JP 2018013395 A JP2018013395 A JP 2018013395A JP 2019034924 A JP2019034924 A JP 2019034924A
- Authority
- JP
- Japan
- Prior art keywords
- lactoferrin
- agent
- astaxanthin
- during pregnancy
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 18
- 210000003754 fetus Anatomy 0.000 title claims abstract description 13
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 68
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 65
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 65
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 65
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 65
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 42
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 42
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 42
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 42
- 239000001168 astaxanthin Substances 0.000 claims abstract description 42
- 230000035935 pregnancy Effects 0.000 claims abstract description 37
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 31
- 235000013305 food Nutrition 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 230000008774 maternal effect Effects 0.000 claims description 11
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 10
- 230000001605 fetal effect Effects 0.000 claims description 10
- 208000015994 miscarriage Diseases 0.000 claims description 10
- 208000000995 spontaneous abortion Diseases 0.000 claims description 10
- 235000019786 weight gain Nutrition 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004584 weight gain Effects 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 238000010606 normalization Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 8
- 235000020824 obesity Nutrition 0.000 abstract description 8
- 208000008589 Obesity Diseases 0.000 abstract description 7
- 230000005856 abnormality Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 235000009200 high fat diet Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- -1 salmon Natural products 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000025972 Maternal Obesity Diseases 0.000 description 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 3
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 208000004104 gestational diabetes Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 108010038047 apolactoferrin Proteins 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000002254 stillbirth Diseases 0.000 description 2
- 231100000537 stillbirth Toxicity 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009233 Morning Sickness Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 1
- 206010049040 Weight fluctuation Diseases 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 150000001514 astaxanthins Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
また、妊婦が肥満や糖尿病を有する場合、胎児のサイズは妊娠6か月時点で既に大きくなっており、BMI≧30である肥満女性が妊娠した場合、胎児が巨大になることによる難産、妊婦の高血圧症候群や糖尿病の発症、胎児の神経管閉鎖障害、死産などのリスクが高くなる傾向が統計学的にも示されている。さらに、そのような母親から生まれる新生児は、過大に育ちがちで、巨大児になることも報告されている。
〔1〕 アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、妊娠中の母体及び胎児の健康状態改善用剤;
〔2〕 医薬組成物又は飲食物である、前記〔1〕又は〔2〕記載の剤;
〔3〕 健康状態改善が、体重増加抑制、血糖値制御、流産率低下又は胎児体重正常化を含む、前記〔1〕又は〔2〕記載の剤;
〔4〕 妊娠中の母体及び胎児の健康状態改善用剤を製造するための、アスタキサンチン及び/又はラクトフェリンの使用;
〔5〕 アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、妊娠中の母体及び胎児の体重増加抑制又は体重正常化用剤;
〔6〕 アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、妊娠中の母体及び胎児の血糖値制御用剤;
〔7〕 アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、流産予防用剤
を提供する。
牛乳から抽出したラクトフェリン原末(蛋白質として純度95%以上;蛋白質中のラクトフェリンは90%以上)20kgに、乳糖45.6kg、結晶セルロース(商品名:アビセル)16kg、カルボキシメチルセルロース・カルシウム塩1.6kg、ショ糖脂肪酸エステル0.8kgを加え、得られた混合物をミキサーで粉砕し、100メッシュを通過する粉末とした。この混合粉末を打錠機により打錠して、長径8.5mm、重量210mgの錠剤とした。1錠中には、ラクトフェリン原末50mgが含有されている。
コーティング機(フロイント産業(株)製、ハイコーターHCT−48N)に、実施例1で製造した錠剤を入れた。この錠剤に、シェラック9.6質量%、L−アルギニン1.5質量%、ソルビトール1.9質量%、ショ糖脂肪酸エステル2.4質量%、エタノール4.8質量%、精製水79.8%よりなる腸溶性コーティング液を噴霧し、対錠剤比で8〜9質量%の腸溶性コーティングを施して製品とした。
<マウスの飼育方法>
4週齢のICRメスマウスを30匹購入し、体重のばらつきが均等になるように4群に分けた。動物飼育環境は、温度23.5±2℃、湿度50±10%、12時間照明(明期6:00−18:00、暗期18:00−6:00)に制御した。
4週齢から15週齢までの間、週に一度の頻度で体重を測定し、餌・水の種類による体重増加を調べた。また産仔の体重は、産後1日目に測定し、出生時体重とした。
4週齢から15週齢までの間、餌の摂取量は週に2回、水の摂取量は週に3回、消費量を測定した。測定値をケージ内のマウス匹数で割り算をし、1匹あたりの1日摂取量を算出した。
出産1週間後のマウスを安楽死させる際、血液を採取した。その血液の一部を実験動物用グルコース測定装置(LAB Gluco、4239R1001、LG用センサー、4239R1002、株式会社フォラケアジャパン)で測定し、血中グルコース濃度を調べた。
出産1週間後のマウスを安楽死させた後、子宮を観察して着床痕の数を調べた。実際に生んだ数を着床痕の数で割った値(%)を出産率とし、100%から出産率を引いた値を流産率とした。
結果を図2〜9に示す。
高脂肪飼料を与えた群(N−HF)は、通常飼料を与えた群(N−N)と比較して、有意に体重が増加した(p<0.01)。それに対し、高脂肪飼料とラクトフェリンを同時摂取させると(LF−HF)、高脂肪飼料のみを与えた群(N−HF)に比べて体重が減少し、通常飼料群(N−N)に近くなる傾向となった(図2)。
Claims (7)
- アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、妊娠中の母体及び胎児の健康状態改善用剤。
- 医薬組成物又は飲食物である、請求項1記載の剤。
- 健康状態改善が、体重増加抑制、血糖値制御、流産率低下又は胎児体重正常化を含む、請求項1又は2記載の剤。
- 妊娠中の母体及び胎児の健康状態改善用剤を製造するための、アスタキサンチン及び/又はラクトフェリンの使用。
- アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、妊娠中の母体及び胎児の体重増加抑制又は体重正常化用剤。
- アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、妊娠中の母体及び胎児の血糖値制御用剤。
- アスタキサンチン及び/又はラクトフェリンを有効成分として含有することを特徴とする、流産予防用剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017155941 | 2017-08-10 | ||
JP2017155941 | 2017-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019034924A true JP2019034924A (ja) | 2019-03-07 |
Family
ID=65636927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018013395A Pending JP2019034924A (ja) | 2017-08-10 | 2018-01-30 | 妊娠中の母子の健康状態改善剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2019034924A (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008100935A (ja) * | 2006-10-18 | 2008-05-01 | Morinaga Milk Ind Co Ltd | プレボテラ・インターメディア抑制剤 |
JP2008530034A (ja) * | 2005-02-11 | 2008-08-07 | テクノロジー バイオラクティス インコーポレイティド | プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス(Lactobacilluskefiranofaciens)の使用 |
JP2012526527A (ja) * | 2009-05-12 | 2012-11-01 | ネステク ソシエテ アノニム | ラクトフェリン、並びに成人における脳の健康及び保護 |
CN103040797A (zh) * | 2013-01-18 | 2013-04-17 | 新乡医学院 | 虾青素在制备防治有机磷农药所致胚胎毒性的药物中的应用 |
CN105192072A (zh) * | 2015-09-10 | 2015-12-30 | 浙江康诺邦健康产品有限公司 | 一种营养素和孕妇配方奶粉 |
-
2018
- 2018-01-30 JP JP2018013395A patent/JP2019034924A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008530034A (ja) * | 2005-02-11 | 2008-08-07 | テクノロジー バイオラクティス インコーポレイティド | プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス(Lactobacilluskefiranofaciens)の使用 |
JP2008100935A (ja) * | 2006-10-18 | 2008-05-01 | Morinaga Milk Ind Co Ltd | プレボテラ・インターメディア抑制剤 |
JP2012526527A (ja) * | 2009-05-12 | 2012-11-01 | ネステク ソシエテ アノニム | ラクトフェリン、並びに成人における脳の健康及び保護 |
CN103040797A (zh) * | 2013-01-18 | 2013-04-17 | 新乡医学院 | 虾青素在制备防治有机磷农药所致胚胎毒性的药物中的应用 |
CN105192072A (zh) * | 2015-09-10 | 2015-12-30 | 浙江康诺邦健康产品有限公司 | 一种营养素和孕妇配方奶粉 |
Non-Patent Citations (5)
Title |
---|
JOURNAL OF FUNCTIONAL FOOD, vol. 22, JPN6021042421, 2016, pages 189 - 200, ISSN: 0004778375 * |
PROCESS BIOCHEMISTRY, vol. 45, JPN6021042420, 2010, pages 1406 - 1414, ISSN: 0004778374 * |
糖尿病ケア, vol. 13, no. 11, JPN6022019049, 2016, pages 1027 - 1029, ISSN: 0004938973 * |
臨床と研究, vol. 7, JPN6021042422, 2011, pages 74 - 79, ISSN: 0004778376 * |
薬局, vol. 66, no. 1, JPN6022019050, 2015, pages 96 - 101, ISSN: 0004938972 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Greenwood et al. | Consequences of intra-uterine growth retardation for postnatal growth, metabolism and pathophysiology | |
McClellan et al. | Evolution of lactation: nutrition v. protection with special reference to five mammalian species | |
Wang et al. | High concentration of vitamin E supplementation in sow diet during the last week of gestation and lactation affects the immunological variables and antioxidative parameters in piglets | |
Mahboub et al. | Effect of maternal feeding in late pregnancy on behaviour and performance of Egyptian goat and sheep and their offspring | |
EP3177154B1 (en) | Myo-inositol and probiotics, and their use to prevent excess body weight in infants | |
KR20210136059A (ko) | 실행 기능 향상에 사용되기 위한 인간 모유 올리고당 | |
EP1776956B1 (en) | Preventive and/or therapeutic agent for calcipenia | |
JP2019034924A (ja) | 妊娠中の母子の健康状態改善剤 | |
Dodd et al. | The pharmacology of bipolar disorder during pregnancy and breastfeeding | |
JP2021504360A (ja) | 多嚢胞性卵巣症候群に罹患している女性患者における胚着床率を高める方法 | |
RU2450825C2 (ru) | Применение лептина для предотвращения избыточной массы тела и композиции, содержащие лептин | |
JP5899773B2 (ja) | 更年期障害改善用医薬組成物ならびに飲食物 | |
JP2021078397A (ja) | 脂質減少促進剤 | |
JP6534439B2 (ja) | 非糖尿病の雌性哺乳動物において生殖能力及び正常な妊孕力を刺激するための及び生殖補助医療の有効性を改善させるための、不妊症の治療に使用されるタングステン(vi)塩 | |
RU2817251C1 (ru) | Кормовая добавка для жвачных животных на основе наночастиц селена и аспарагината кобальта | |
Oyelowo et al. | Developmental consequences of in-utero exposure to omega-9 monounsaturated fatty acid and its sex-skewing potential in rats | |
JP5022454B2 (ja) | 卵巣機能改善剤 | |
JP5697128B2 (ja) | 胎児期及び乳児期等の哺乳動物へのCoQ10の新規用途 | |
RU2731271C2 (ru) | Способ профилактики жирового гепатоза печени у лактирующих коров | |
JP6082941B2 (ja) | 更年期障害改善用医薬組成物ならびに飲食物 | |
JP4893914B2 (ja) | 経管栄養組成物 | |
Ward | Management of sows and their piglets around the periparturient period: observing the effects on survival and performance of the litter | |
WO2019146652A1 (ja) | 抗i型アレルギー剤、及び肥満細胞又は好塩基球の脱顆粒抑制剤、並びに抗認知症剤、及び短期記憶障害改善/抑制剤 | |
Fuchs et al. | Neonatal hypoglycemia in dogs—pathophysiology, risk factors, diagnosis and treatment | |
Schroeder | Effects of ꙍ6: ꙍ3 Fatty Acid Supplementation During Prepartum Period to Dairy Cows on Immunity and Performance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20180130 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180215 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220721 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221107 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221107 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221116 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221121 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221209 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240522 |